NCT05726734

Vonoprazan-containing Triple Therapy Versus Empiric Bismuth Quadruple Therapy for First-line Helicobacter Pylori Treatment: a Randomized Clinical Trial

Efficacy of Vonoprazan-containing Triple Therapy Versus Empiric Bismuth Quadruple Therapy for First-line Helicobacter Pylori Treatment: a Randomized Clinical Trial

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Shanghai East Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Vonoprazan Amoxicillin and metronidazole based triple therapy had achieved a high cure rate in the rescue treatment of helicobacter pylori infection. This study aims to evaluate the efficacy and safety of the Vonoprazan, amoxicillin and metronidazole based triple therapy and the empiric bismuth quadruple therapy in the naive patients with Helicobacter pylori infection.

Conditions

• Helicobacter Pylori Infection

Interventions

Type	Name	Description
DRUG	Vonoprazan	potassium-competitive acid blocker
DRUG	Amoxicillin, Metronidazole	Antibiotics for H. pylori eradication
DRUG	Bismuth Potassium Citrate	Gastric mucosal protective drug with anti-H. pylori effect
DRUG	Esomeprazole	Proton pump inhibitor

Timeline

• Start date: 2023-02-06
• Primary completion: 2025-02-06
• Completion: 2026-02-06
• First posted: 2023-02-14
• Last updated: 2023-02-14

Locations

1 site across 1 country: China